(SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture ... epilepsy treatment is expected to grow to US$1.8 billion by 2032, with North America accounting for some ...

U.S. sales of the treatment ... accounting for 47 percent of the global market. SK Biopharm stated that the two companies have secured the funding to develop and operate the joint venture for ...